Amber Tong – Page 30 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

Churn in FDA’s inspection unit; Roche’s changing of the guard; Illumina on defense; NASH believer finds new ...

3 years ago

Astellas gathers scattered cell and gene therapy, BD units in new $70M South San Francisco hub

3 years ago

Biden to tap Harvard surgeon, clinical trials expert as NCI director

3 years ago

John McHutchison throws in the towel on HBV drug, triggering layoffs as Assembly shifts to next-gen approaches

3 years ago

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into ...

3 years ago

After 14 years as Roche’s CEO, Severin Schwan is passing the baton

3 years ago

Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares

3 years ago

San Francisco cell therapy player lays off 94 staffers as it awaits data on lead candidate

3 years ago

As the pandemic high wanes, Inovio chops headcount again while chasing Covid win

3 years ago

Safety scare cleared and early data in hand, Ultragenyx dishes out $75M to buy rare disease partner

3 years ago

Weeks after rare disease drug got spurned, Acer returns to FDA for second shot

3 years ago

Oxford Science Enterprises collects $300M to offer spinouts 'scale-up capital'

3 years ago

Novartis' big PD-1 bet turns sour; $350M resurrection story; Contraceptive for men heads to clinic; and more

3 years ago

After initial commercial foray, China's CStone mulls sale — report

3 years ago

Novartis’ $650M cash bet on a near-term FDA OK for BeiGene’s China PD-1? It just got delayed indefinitely

3 years ago

Reeling from PhII flop, CytomX lays off 40% as execs go back to drawing board, seek new deals

3 years ago

Curtain-raiser data keep analysts on edge ahead of Amgen’s big Lumakras/PD-1 combo readout

3 years ago

Gene editing for heart disease: Verve kicks off landmark base editing trial

3 years ago

Can positive but exploratory data entice investors to $150M raise in a bear market? Pliant will find out

3 years ago

Updated: Different way to go after KRAS mutant tumors? Novo-backed biotech nabs $50M to wrap early studies

3 years ago

VC dollars keep rolling in as Qiming ties a ribbon on $2.5B Fund VIII

3 years ago

In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial

3 years ago

Bispecific M&A reaches AstraZeneca; Countdown for Merck's big bid; Biotech buyout in savage times; and more

3 years ago

AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector

3 years ago

First page Previous page 27 28 293031 32 33 Next page Last page